Elekta (OTCMKTS:EKTAY) Sees Large Volume Increase – Still a Buy?

Shares of Elekta AB (OTCMKTS:EKTAY) saw unusually-high trading volume on Friday . 3,728 shares changed hands during trading, an increase of 26% from the previous session’s volume of 2,960 shares.The stock last traded at $5.57 and had previously closed at $5.4150.

Analysts Set New Price Targets

Separately, Zacks Research raised Elekta from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Elekta Stock Performance

The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of -34.81 and a beta of 1.01. The company’s fifty day simple moving average is $5.14 and its 200 day simple moving average is $5.75. The company has a quick ratio of 0.68, a current ratio of 0.87 and a debt-to-equity ratio of 0.47.

Elekta (OTCMKTS:EKTAY) last posted its earnings results on Thursday, May 28th. The company reported $0.06 earnings per share (EPS) for the quarter. The company had revenue of $521.00 million during the quarter. Elekta had a negative net margin of 3.32% and a positive return on equity of 11.11%. On average, equities research analysts expect that Elekta AB will post 0.43 earnings per share for the current year.

About Elekta

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.